Survival will out

Dendreon Corp. had its sights set on obtaining approval of its Provenge immunotherapy to treat only those prostate cancer patients with Gleason scores of 7 or less after the compound missed the primary endpoint in a broader patient population in the company's first Phase III trial. But 36-month survival data from the trial

Read the full 537 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE